Kancera is a clinical stage biotech developing a new class of small molecule drugs with an immune cell modulating mode-of-action with focus on cardiovascular diseases. The lead program KAND567 is in clinical phase II-stage and is aiming to prevent reperfusion injury that may occur in connection with percutaneous coronary intervention in acute myocardial infarction.
The stock is traded on the Nasdaq First North Premier Growth Market.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Nanna Svarts Väg 4, Solna,17165,sweden
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- kancera.se
- HQ
- Solna
Kancera Questions
Kancera's website is kancera.se
Kancera's LinkedIn profile is https://se.linkedin.com/company/kancera-ab
Kancera has
8 employees.
View email and phone details for 8
employees at Kancera.
Kancera's industry is
Biotechnology Research
Kancera's top competitors are
Mendus Ab,
Alzecure Pharma,
Oncopeptides Ab (Publ),
Medivir Ab,
Bioarctic,
Calliditas Therapeutics,
Alzinova Ab,
Pelago Bioscience Ab,
Alligator Bioscience Ab,
Anocca.
Kancera's categories are Biotechnology Research
Kancera's founding year is 2010
